2024+KDIGO临床实践指南:慢性肾脏病的评估和管理.pdf
《2024+KDIGO临床实践指南:慢性肾脏病的评估和管理.pdf》由会员分享,可在线阅读,更多相关《2024+KDIGO临床实践指南:慢性肾脏病的评估和管理.pdf(198页珍藏版)》请在咨信网上搜索。
1、KDIGO 2024 CLINICAL PRACTICE GUIDELINEFOR THE EVALUATION AND MANAGEMENTOF CHRONIC KIDNEY DISEASEKidney International(2024)105(Suppl 4S),S117S314S117KDIGO 2024 Clinical Practice Guideline for the Evaluation andManagement of Chronic Kidney DiseaseS118Tables,figures,and supplementary materialS124KDIGO
2、Executive CommitteeS125Reference keysS126CKD nomenclatureS127Conversion factorsS128Abbreviations and acronymsS129NoticeS130ForewordS131Work Group membershipS133AbstractS134Patient forewordS135Introduction,qualifying statements,and key conceptsS141Special considerationsS144Summary of relative and abs
3、olute risks relevant to CKD from meta-analysis oflarge multinational population studies in the CKD Prognosis Consortium(CKD-PC)S149Summary of recommendation statements and practice pointsS169Chapter 1:Evaluation of CKDS196Chapter 2:Risk assessment in people with CKDS205Chapter 3:Delaying CKD progres
4、sion and managing its complicationsS246Chapter 4:Medication management and drug stewardship in CKDS255Chapter 5:Optimal models of careS270Chapter 6:Research recommendationsS274Methods for guideline developmentS283Biographic and disclosure informationS294AcknowledgmentsS295ReferencesThis article is p
5、ublished as part of a supplement sponsored by Kidney Disease:Improving Global Outcomes(KDIGO).Theopinions or views expressed in this supplement are those of the authors and do not necessarily reflect the opinions or rec-ommendations of the International Society of Nephrology or Elsevier.Dosages,indi
6、cations,and methods of use for productsthat are referred to in the supplement by the authors may reflect their clinical experience or may be derived from the pro-fessional literature or other clinical sources.Because of the differences between in vitro and in vivo systems and betweenlaboratory anima
7、l models and clinical data in humans,in vitro and animal data do not necessarily correlate with clinical results.contentswww.kidney-international.orgVOL 105|ISSUE 4S|APRIL 2024S118Kidney International(2024)105(Suppl 4S),S117S314TABLESS137Table 1.Criteria for chronic kidney diseaseS137Table 2.GFR cat
8、egories in CKDS137Table 3.Albuminuria categories in chronic kidney disease(CKD)S169Table 4.Use of GFR and albuminuriaS171Table 5.Risk factors for CKDS174Table 6.Guidance for selection of additional tests for evaluation of causeS178Table 7.Description of initial and supportive tests for evaluation of
9、 GFRS179Table 8.Indications for use of cystatin CS180Table 9.Comparison of estimated GFR and measured GFRS181Table 10.Indications for measured GFRS184Table 11.Implementation standards to ensure accuracy and reliability of GFR assessments using creatinine andcystatin CS184Table 12.Reported examples o
10、f substances that may cause analytical interferences in creatinine assaysS187Table 13.Criteria for a validated GFR estimating equationS189Table 14.Validated GFR estimating equationsS190Table 15.Criteria for equation comparison for comparison of candidate equations to another(i.e.,how todetermine val
11、idity)S191Table 16.Factors causing biological variation in urine albumin or urine proteinS193Table 17.Implementation standards to ensure accuracy and reliability of urine samplesS198Table 18.Impact of albuminuria/proteinuria on CKD progression in pediatricsS199Table 19.Externally validated risk equa
12、tions for predicting kidney failure in the general(CKD G3G5)populationS203Table 20.Externally validated risk equations for predicting a 40%decline in GFRS209Table 21.Impact of plant-based foods in people with CKDS212Table 22.Age-based sodium intake recommendationsS222Table 23.Variation of laboratory
13、 values in a large population database by age group,sex,and eGFR;bicarbonate,mmol/l,mean(SD),n 3,990,898S223Table 24.Variation of laboratory values in a large population database by age group,sex,and eGFR;potassium,mmol/l,mean(SD),n 4,278,600S225Table 25.Factors and mechanisms that impact on potassi
14、um measurementsS226Table 26.Medications associated with increased risk of hyperkalemiaS227Table 27.A comparison of potassium exchange agentsS227Table 28.Suggested action in the event of moderate and severe hyperkalemiaS229Table 29.Variation of laboratory values in a large population database by age
15、group,sex,and eGFR;hemoglobin,g/dl,mean(SD),n 3,561,622S233Table 30.Randomized controlled trials in the treatment of asymptomatic hyperuricemia in people with CKDS247Table 31.Key examples of common medications with documented nephrotoxicity and,where available,selectednon-nephrotoxic alternativesS25
16、2Table 32.Medications that should be considered for temporary discontinuation before elective surgeries andpotential perioperative adverse events associated with their continued useS253Table 33.Potential risk factors for contrast-associated acute kidney injuryS256Table 34.Benefits and consequences o
17、f early versus late referralS257Table 35.Factors associated with late referral for kidney replacement therapy planningS257Table 36.Outcomes examined in a systematic review by Smart et al.S258Table 37.Recommended patient-reported outcome measurement tools for use in people with CKDwww.kidney-internat
18、ional.orgcontentsKidney International(2024)105(Suppl 4S),S117S314S119S259Table 38.Management strategies for common symptoms in CKDS261Table 39.List of validated assessment tools for malnutritionS262Table 40.Key features of existing CKD care modelsS266Table 41.Indications for the initiation of dialys
19、isS267Table 42.Studies examining the timing of dialysis in people with CKDS268Table 43.People with kidney failure who receive comprehensive conservative careS275Table 44.Clinical questions and systematic review topics in PICOS formatS280Table 45.Classification for certainty of evidenceS280Table 46.G
20、RADE system for grading the certainty of evidenceS281Table 47.KDIGO nomenclature and description for grading recommendationsS281Table 48.Determinants of the strength of recommendationFIGURESS136Figure 1.Associations of chronic kidney disease(CKD)staging by estimated glomerular filtration rate bycrea
21、tinine and cystatin C(eGFRcr-cys)and albumin-to-creatinine ratio(ACR)categories and risks for10 common complications by age in multivariable-adjusted analysesS138Figure 2.Age-standardized chronic kidney disease disability-adjusted life-year(DALY)rates for each location bysociodemographic index,both
22、sexes combined,2019S139Figure 3.Screening algorithm for diagnosis and staging of chronic kidney disease(CKD)in adultsS141Figure 4.Special considerations for chronic kidney disease(CKD)care across the lifespanS145Figure 5.Associations of chronic kidney disease(CKD)staging by estimated glomerular filt
23、ration rate bycreatinine(eGFRcr)and albumin-to-creatinine ratio(ACR)categories and risks for 10 commoncomplications in multivariable-adjusted analysesS146Figure 6.Associations of chronic kidney disease(CKD)staging by estimated glomerular filtration rate bycreatinine and cystatin C(eGFRcr-cys)and alb
24、umin-to-creatinine ratio categories and risks for 10common complications in multivariable-adjusted analysesS147Figure 7.Hazard ratios for adverse outcomes using the continuous model of estimated glomerular filtration rate(eGFR),comparison of the shape of associations between creatinine-based eGFR(eG
25、FRcr)andcreatinine and cystatin Cbased eGFR(eGFRcr-cys)in the population with cystatin C(eGFRcr-cyspopulation)S173Figure 8.Evaluation of cause of chronic kidney disease(CKD)S174Figure 9.Actionable genes in kidney diseaseS175Figure 10.Proposed organization for implementing genetics in nephrologyS177F
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 2024 KDIGO 临床 实践 指南 慢性 肾脏病 评估 管理
1、咨信平台为文档C2C交易模式,即用户上传的文档直接被用户下载,收益归上传人(含作者)所有;本站仅是提供信息存储空间和展示预览,仅对用户上传内容的表现方式做保护处理,对上载内容不做任何修改或编辑。所展示的作品文档包括内容和图片全部来源于网络用户和作者上传投稿,我们不确定上传用户享有完全著作权,根据《信息网络传播权保护条例》,如果侵犯了您的版权、权益或隐私,请联系我们,核实后会尽快下架及时删除,并可随时和客服了解处理情况,尊重保护知识产权我们共同努力。
2、文档的总页数、文档格式和文档大小以系统显示为准(内容中显示的页数不一定正确),网站客服只以系统显示的页数、文件格式、文档大小作为仲裁依据,平台无法对文档的真实性、完整性、权威性、准确性、专业性及其观点立场做任何保证或承诺,下载前须认真查看,确认无误后再购买,务必慎重购买;若有违法违纪将进行移交司法处理,若涉侵权平台将进行基本处罚并下架。
3、本站所有内容均由用户上传,付费前请自行鉴别,如您付费,意味着您已接受本站规则且自行承担风险,本站不进行额外附加服务,虚拟产品一经售出概不退款(未进行购买下载可退充值款),文档一经付费(服务费)、不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
4、如你看到网页展示的文档有www.zixin.com.cn水印,是因预览和防盗链等技术需要对页面进行转换压缩成图而已,我们并不对上传的文档进行任何编辑或修改,文档下载后都不会有水印标识(原文档上传前个别存留的除外),下载后原文更清晰;试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓;PPT和DOC文档可被视为“模板”,允许上传人保留章节、目录结构的情况下删减部份的内容;PDF文档不管是原文档转换或图片扫描而得,本站不作要求视为允许,下载前自行私信或留言给上传者【老金】。
5、本文档所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用;网站提供的党政主题相关内容(国旗、国徽、党徽--等)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。
6、文档遇到问题,请及时私信或留言给本站上传会员【老金】,需本站解决可联系【 微信客服】、【 QQ客服】,若有其他问题请点击或扫码反馈【 服务填表】;文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“【 版权申诉】”(推荐),意见反馈和侵权处理邮箱:1219186828@qq.com;也可以拔打客服电话:4008-655-100;投诉/维权电话:4009-655-100。